Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Cozzi-Lepri

Showing results (121-130 of 244) with videos related to

Pageof 25
Sort By:
Antiviral Therapy|March 8, 2006
Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapyMariacarmela Solmone, Enrico Girardi, Eleonora Lalle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 12, 2008
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA StudyWendy P Bannister, Alessandro Cozzi-Lepri, Bonaventura Clotet, et al.
Plos One|November 1, 2017
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general populationAntonella Cingolani, Alessandro Cozzi Lepri, Luciana Teofili, et al.
Journal of Internal Medicine|November 13, 2024
Incidence and predictors of clinical failure after early treatment for mild-to-moderate COVID-19 in high-risk individuals: A multicentric cohort studyIlaria Mastrorosa, Alessandro Cozzi Lepri, Cosmo Del Borgo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 13, 2016
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized TherapyAntonio Di Biagio, Alessandro Cozzi-Lepri, Roberta Prinapori, et al.
AIDS (London, England)|July 18, 2022
The contribution of late HIV diagnosis on the occurrence of HIV-associated tuberculosisEnrico Girardi, Yanink Caro-Vega, Alessandro Cozzi-Lepri, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 6, 2025
Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohortMariacristina Poliseno, Sergio Lo Caputo, Alessandro Tavelli, et al.
AIDS (London, England)|June 20, 2015
HIV resistance testing and detected drug resistance in EuropeAnna Schultze, Andrew N Phillips, Roger Paredes, et al.
Journal of the International AIDS Society|November 15, 2014
Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppressionJosep M Llibre, Alessandro Cozzi-Lepri, Jorge Antonio Valencia La Rosa, et al.
HIV Medicine|December 2, 2024
Predictors for choosing doravirine-based versus INSTI-based regimen in ART-naïve and ART-experienced people with HIV in real-world setting: Data from the Icona cohortAntonella d'Arminio Monforte, Alessandro Tavelli, Eugenia Quiros-Roldan, et al.
Pageof 25

Showing results (121-130 of 244) with videos related to

Sort By:
Pageof 25
Antiviral Therapy|March 8, 2006
Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapyMariacarmela Solmone, Enrico Girardi, Eleonora Lalle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 12, 2008
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA StudyWendy P Bannister, Alessandro Cozzi-Lepri, Bonaventura Clotet, et al.
Plos One|November 1, 2017
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general populationAntonella Cingolani, Alessandro Cozzi Lepri, Luciana Teofili, et al.
Journal of Internal Medicine|November 13, 2024
Incidence and predictors of clinical failure after early treatment for mild-to-moderate COVID-19 in high-risk individuals: A multicentric cohort studyIlaria Mastrorosa, Alessandro Cozzi Lepri, Cosmo Del Borgo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 13, 2016
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized TherapyAntonio Di Biagio, Alessandro Cozzi-Lepri, Roberta Prinapori, et al.
AIDS (London, England)|July 18, 2022
The contribution of late HIV diagnosis on the occurrence of HIV-associated tuberculosisEnrico Girardi, Yanink Caro-Vega, Alessandro Cozzi-Lepri, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 6, 2025
Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohortMariacristina Poliseno, Sergio Lo Caputo, Alessandro Tavelli, et al.
AIDS (London, England)|June 20, 2015
HIV resistance testing and detected drug resistance in EuropeAnna Schultze, Andrew N Phillips, Roger Paredes, et al.
Journal of the International AIDS Society|November 15, 2014
Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppressionJosep M Llibre, Alessandro Cozzi-Lepri, Jorge Antonio Valencia La Rosa, et al.
HIV Medicine|December 2, 2024
Predictors for choosing doravirine-based versus INSTI-based regimen in ART-naïve and ART-experienced people with HIV in real-world setting: Data from the Icona cohortAntonella d'Arminio Monforte, Alessandro Tavelli, Eugenia Quiros-Roldan, et al.
Pageof 25